Audrey Putoux

Dr. Audrey Putoux

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2011 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
APAudrey Putoux
Audrey Putoux
Sophie ThomasSophie Thomas
Sophie Thomas
KCKarlien L M Coene
Karlien L M Coene
EDErica Davis
Erica Davis
YAYasemin Alanay
Yasemin Alanay
TATania Attié-Bitach
Tania Attié-Bitach

1 November 2011 in Human Mutation
Verified
Journal Article
Closed access
PDF file
SWSandra Whalen
Sandra Whalen
DHDelphine Héron
Delphine Héron
TGThierry Gaillon
Thierry Gaillon
OMOana Moldovan
Oana Moldovan
MRMassimiliano Rossi
Massimiliano Rossi
IGIrina Giurgea
Irina Giurgea
Pitt–Hopkins syndrome (PTHS), characterized by severe intellectual disability and typical facial gestalt, is part of the clinical spectrum of Rett‐like syndromes. TCF4, encoding a basic helix‐loop‐helix (bHLH) transcription factor, was identified as the disease‐causing gene with de novo molecular defects. While PTHS appears to be a recognizable clinical entity, it seems to remain underdiagnosed, especially when facial gestalt is less typical. With the aim to facilitate the diagnosis of PTHS and to increase its rate and specificity, we have investigated 33 novel patients and defined a Clinical Diagnosis Score. Analysis of 112 individuals (79 previously reported and 33 novel patients) allowed us to delineate the TCF4 mutational spectrum, with 40% point mutations, 30% small deletions/insertions, and 30% deletions. Most of these were private mutations and generated premature stop codons. Missense mutations were localized in the bHLH domain, which is a mutational hotspot. No obvious difference was observed between patients harboring truncating, missense mutations, or deletions, further supporting TCF4 haploinsufficiency as the molecular mechanism underlying PTHS. In this study, we have summarized the current knowledge of TCF4 molecular pathology, reported all the mutations in the TCF4 database (http://www.LOVD.nl/TCF4), and present a novel and comprehensive diagnostic strategy for PTHS. Hum Mutat 33:64–72, 2012.

19 January 2011 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
APAudrey Putoux
Audrey Putoux
TATania Attié-Bitach
Tania Attié-Bitach
JMJéléna Martinovic
Jéléna Martinovic
MGMarie-Claire Gubler
Marie-Claire Gubler

28 March 2019 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
CSCaroline Schluth-Bolard
Caroline Schluth-Bolard
FDFlavie Diguet
Flavie Diguet
NCNicolas Chatron
Nicolas Chatron
PRPierre-Antoine Rollat-Farnier
Pierre-Antoine Rollat-Farnier
CBClaire Bardel
Claire Bardel
DSDamien Sanlaville
Damien Sanlaville
Background: Balanced chromosomal rearrangements associated with abnormal phenotype are rare events, but may be challenging for genetic counselling, since molecular characterisation of breakpoints is not performed routinely. We used next-generation sequencing to characterise breakpoints of balanced chromosomal rearrangements at the molecular level in patients with intellectual disability and/or congenital anomalies. Methods: Breakpoints were characterised by a paired-end low depth whole genome sequencing (WGS) strategy and validated by Sanger sequencing. Expression study of disrupted and neighbouring genes was performed by RT-qPCR from blood or lymphoblastoid cell line RNA. Results: Among the 55 patients included (41 reciprocal translocations, 4 inversions, 2 insertions and 8 complex chromosomal rearrangements), we were able to detect 89% of chromosomal rearrangements (49/55). Molecular signatures at the breakpoints suggested that DNA breaks arose randomly and that there was no major influence of repeated elements. Non-homologous end-joining appeared as the main mechanism of repair (55% of rearrangements). A diagnosis could be established in 22/49 patients (44.8%), 15 by gene disruption (KANSL1, FOXP1, SPRED1, TLK2, MBD5, DMD, AUTS2, MEIS2, MEF2C, NRXN1, NFIX, SYNGAP1, GHR, ZMIZ1) and 7 by position effect (DLX5, MEF2C, BCL11B, SATB2, ZMIZ1). In addition, 16 new candidate genes were identified. Systematic gene expression studies further supported these results. We also showed the contribution of topologically associated domain maps to WGS data interpretation. Conclusion: Paired-end WGS is a valid strategy and may be used for structural variation characterisation in a clinical setting.

12 September 2018 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
CMCyril Mignot
Cyril Mignot
AMAoife C. McMahon
Aoife C. McMahon
CBClaire Bar
Claire Bar
PCPhilippe M Campeau
Philippe M Campeau
CDClaire Davidson
Claire Davidson
CDChristel Depienne
Christel Depienne
Purpose Variants in IQSEC2, escaping X inactivation, cause X-linked intellectual disability with frequent epilepsy in males and females. We aimed to investigate sex-specific differences. Methods We collected the data of 37 unpublished patients (18 males and 19 females) with IQSEC2 pathogenic variants and 5 individuals with variants of unknown significance and reviewed published variants. We compared variant types and phenotypes in males and females and performed an analysis of IQSEC2 isoforms. Results IQSEC2 pathogenic variants mainly led to premature truncation and were scattered throughout the longest brain-specific isoform, encoding the synaptic IQSEC2/BRAG1 protein. Variants occurred de novo in females but were either de novo (2/3) or inherited (1/3) in males, with missense variants being predominantly inherited. Developmental delay and intellectual disability were overall more severe in males than in females. Likewise, seizures were more frequently observed and intractable, and started earlier in males than in females. No correlation was observed between the age at seizure onset and severity of intellectual disability or resistance to antiepileptic treatments. Conclusion This study provides a comprehensive overview of IQSEC2-related encephalopathy in males and females, and suggests that an accurate dosage of IQSEC2 at the synapse is crucial during normal brain development.

25 March 2014 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
EDEstelle Dubruc
Estelle Dubruc
APAudrey Putoux
Audrey Putoux
ALAudrey Labalme
Audrey Labalme
CRChristelle Rougeot
Christelle Rougeot
DSDamien Sanlaville
Damien Sanlaville
PEPatrick Edery
Patrick Edery